resistanceBio

resistance.bio

Resistance Bio is the first platform that generates real resistance data to solve drug resistance, which is responsible for 90% of cancer mortality. The company focuses on understanding and preventing drug resistance from the start, recognizing that while drugs are tested for 2-4 weeks, clinical resistance can take over 3 months to evolve. By combining advanced biotechnology with long-term evolution, Resistance Bio aims to develop longer-lasting drugs, reveal resistance pathways, discover novel targets, and predict clinical outcomes, ultimately advancing drug candidates and approving new drugs faster and cheaper. The market size for ALK in lung cancer is around $3.5 billion, with potential for significant growth through the use of resistance data.

Is this your company?